This paper examines the long-term biological consequences of chronic Δ9-tetrahydrocannabinol (THC) exposure through a systems-level, temporal framework. Rather than treating THC as an acutely acting substance, the work analyses it as a persistent CB1-dominant signalling agent that reshapes regulatory behaviour over time. The paper introduces adaptive capacity as a core biological property and distinguishes short-term symptom relief from long-term system resilience. Drawing on concepts of allostasis, temporal cost, attractor drift, and reduced reversibility, it shows how repeated external signalling can stabilise symptoms while quietly eroding flexibility, recovery dynamics, and independence from ongoing modulation. Across metabolic, autonomic, endocrine, immune, and neuroregulatory domains, chronic CB1 signalling promotes compensatory regulation that accumulates gradually and is poorly captured by short-duration studies or testimonials. The analysis reframes THC-related risk not as toxicity or misuse, but as a predictable outcome of temporal misalignment between acute effects and long-term system behaviour. Severe and refractory conditions, such as certain epilepsies, are explicitly addressed as distinct clinical contexts where acute risk reduction may justify signalling dampening. The paper cautions against extrapolating outcomes from such cases to long-term use in otherwise adaptable systems. This work forms part of a broader series examining context-dependent risks of THC and contributes a unifying temporal framework for evaluating cannabinoid interventions based on preservation of adaptive capacity rather than short-term symptom suppression.
Anwar Mohamed (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: